748 related articles for article (PubMed ID: 19404048)
1. [Statins with a perspective of lifelong therapy].
Ertaş FS
Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048
[TBL] [Abstract][Full Text] [Related]
2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
3. Statin and ezetimibe combination therapy in cardiovascular disease.
Dembowski E; Davidson MH
Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
[TBL] [Abstract][Full Text] [Related]
4. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
5. Management of hyperlipidemia in older adults.
Alexander KP; Blazing MA; Rosenson RS; Hazard E; Aronow WS; Smith SC; Ohman EM
J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):49-58. PubMed ID: 19124599
[TBL] [Abstract][Full Text] [Related]
6. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
Wojakowski W; Gmiński J
Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
[TBL] [Abstract][Full Text] [Related]
7. Achieving vascular risk factor targets: a survey of a London general practice.
Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
[TBL] [Abstract][Full Text] [Related]
8. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease.
Lardizabal JA; Deedwania P
Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102
[TBL] [Abstract][Full Text] [Related]
10. Lipid-lowering therapy today: treating the high-risk cardiovascular patient.
Berra K
J Cardiovasc Nurs; 2008; 23(5):414-21. PubMed ID: 18728514
[TBL] [Abstract][Full Text] [Related]
11. Statins in acute coronary syndromes: do the guideline recommendations match the evidence?
Morrissey RP; Diamond GA; Kaul S
J Am Coll Cardiol; 2009 Oct; 54(15):1425-33. PubMed ID: 19796735
[TBL] [Abstract][Full Text] [Related]
12. Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy.
Rapezzi C; Biagini E; Bellis P; Cafiero M; Velussi M; Ceriello A; Cooke RM; Schweiger C;
J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):878-87. PubMed ID: 18695423
[TBL] [Abstract][Full Text] [Related]
13. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Moyad MA; Merrick GS
Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
[TBL] [Abstract][Full Text] [Related]
15. The past, present, and future of statin therapy.
Watson KE; Fonarow GC
Rev Cardiovasc Med; 2005; 6(3):129-39. PubMed ID: 16195686
[TBL] [Abstract][Full Text] [Related]
16. [Statins in the management of dyslipidemias].
Scheen AJ
Rev Prat; 2011 Oct; 61(8):1120-6. PubMed ID: 22135981
[TBL] [Abstract][Full Text] [Related]
17. Non-adherence to statin therapy: a major challenge for preventive cardiology.
Bates TR; Connaughton VM; Watts GF
Expert Opin Pharmacother; 2009 Dec; 10(18):2973-85. PubMed ID: 19954271
[TBL] [Abstract][Full Text] [Related]
18. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Stewart RA
Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
[TBL] [Abstract][Full Text] [Related]
19. Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy.
Tsang JL; Mendelsohn A; Tan MK; Hackam DG; Leiter LA; Fitchett D; Lin PJ; Grima E; Langer A; Goodman SG;
Am J Cardiol; 2008 Nov; 102(9):1142-5. PubMed ID: 18940280
[TBL] [Abstract][Full Text] [Related]
20. Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease.
Ferdinand KC
Curr Med Res Opin; 2005 Jul; 21(7):1091-7. PubMed ID: 16004678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
